Skip to main content

Cronos Group Inc (CRON-T) Quote - Press Releases

Unchecking box will stop auto data updates
TSX Real-Time Last Sale CAD
Today's Change
Volume
Price Quote as of

More stories below advertisement

Latest Press Releases

How CBD Nanoemulsion Could Highly Optimize Quickly Growing CBD-Infused Products
- MENAFN - Thu Jan 30, 3:47PM CST
MENAFN - CMTX
Thu Jan 30, 3:47PM CST
(MENAFN - Financial News Media) Palm Beach, FL -January 30, 2020 - A decade ago, almost nobody had heard of CBD aside from a handful of researchers. Today it's a different story. The expanding CBD market is estimated to grow at an explosive rate - from $5 billion in 2019 to $23.7 billion by 2023. The infused beverages sub-market is expected to grow at for several years to come. Consumer packaged goods (CPG) companies are poised to become dominant players in the CBD-Infused market. Major medical discoveries are triggering an eruption of new products in consumer packaged goods (CPG) - reaching millions of consumers across different demographics - bringing CBD into the mainstream. Among products that new and existing customers consider trying, accessible forms such as edibles and beverages rank the highest. When CBD is extracted from the plant, it takes an oil-based form. Like any oil it is hydrophobic, meaning it will not dissolve in water. Since our bodies are made of 60% water, CBD oil resists absorption into the bloodstream. The current low levels of CBD bioavailability are putting pressure on the cannabis industry to find a solution for these products. Active cannabis companies in the markets this week include: (OTCQB: PBIO), (NYSE: ACB) (TSX: ACB), (NASDAQ: OGI) (TSX: OGI), (NASDAQ: CRON) (TSX: CRON), (CSE: BOSS) (OTCQB: BOSQF).
How CBD Nanoemulsion Could Highly Optimize Quickly Growing CBD-Infused Products
- PR Newswire - Thu Jan 30, 7:30AM CST
PR Newswire - CMTX
Thu Jan 30, 7:30AM CST
A decade ago, almost nobody had heard of CBD aside from a handful of researchers. Today it's a different story. The expanding CBD market is estimated to grow at an explosive rate - from $5 billion in 2019 to $23.7 billion by 2023. The infused beverages sub-market is expected to grow at for several years to come. Consumer packaged goods (CPG) companies are poised to become dominant players in the CBD-Infused market. Major medical discoveries are triggering an eruption of new products in consumer packaged goods (CPG) - reaching millions of consumers across different demographics - bringing CBD into the mainstream. Among products that new and existing customers consider trying, accessible forms such as edibles and beverages rank the highest. When CBD is extracted from the plant, it takes an oil-based form. Like any oil it is hydrophobic, meaning it will not dissolve in water. Since our bodies are made of 60% water, CBD oil resists absorption into the bloodstream. The current low levels of CBD bioavailability are putting pressure on the cannabis industry to find a solution for these products. Active cannabis companies in the markets this week include: Pressure BioSciences, Inc. (OTCQB: PBIO), Aurora Cannabis Inc. (NYSE: ACB) (TSX: ACB), OrganiGram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON), The Yield Growth Corp. (CSE: BOSS) (OTCQB: BOSQF).
Cronos Group Inc. to Hold 2019 Fourth Quarter and Full-Year Conference Call on February 27, 2020
- GlobeNewswire - Tue Jan 28, 12:30PM CST
GlobeNewswire - CMTX
Tue Jan 28, 12:30PM CST
Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos Group" or the "Company") will hold its 2019 Fourth Quarter and Full-Year Earnings Conference Call on Thursday, February 27, 2020 at 8:30 a.m. EST. Cronos Group's senior management team will discuss its financial results and will be available for questions from the investment community after prepared remarks.
Canada's Edibles, Beverages, and Concentrates Market is an Untapped Goldmine
- PR Newswire - Thu Dec 19, 7:30AM CST
PR Newswire - CMTX
Thu Dec 19, 7:30AM CST
Ever since "Legalization 2.0" was first announced, investors have been looking to it as a fulfillment of the long-promised pot gold rush. As of December 17, consumable pot products can be bought and sold on shelves across Canada and, as such, the industry is undergoing a significant disruption. According to Deloitte, the Canadian market for pot edibles and beverages will be worth $2.7 billion annually, and many of the biggest companies have been scrambling to gain access to that value. Because consumables are an entirely new market, they represent an exciting opportunity for retailers to distinguish themselves, and for investors to separate the minor league pot players from the major league ones. Companies that can take advantage of this exciting sector--such as BevCanna Enterprises Inc. (CSE:BEV) (OTCPK:BVNNF) (FRA:7BC), Canopy Growth Corporation (TSX:WEED) (NYSE:CGC), Cronos Group (TSX:CRON) (NASDAQ:CRON), Aurora Cannabis Inc. (TSX:ACB) (NYSE:ACB), and HEXO Corp. (TSX:HEXO) (NYSE:HEXO) - deserve to have investors' attention, as they stand atop an untapped goldmine in the still burgeoning pot industry.
Plethora of Public Figures Throw Support Behind the Cannabis Market
- PR Newswire - Mon Nov 18, 8:00AM CST
PR Newswire - CMTX
Mon Nov 18, 8:00AM CST
In recent times, more and more celebrities have come out in support of the cannabis industry. Recently, famous Canadian rapper, Drake launched a joint cannabis venture to produce cannabis along with medicinal products and a wide range of clothing apparel. Drake now joins a handful of other celebrities who have also publicly endorsed the use of cannabis. Notably, celebrities such as Snoop Dogg, Wiz Khalifa, Willie Nelson, Jay Z, Martha Stewart, and Rob Gronkowski have all entered into the cannabis marketplace. However, most of the celebrity-backed ventures typically focus on hemp-derived CBD products, even though celebrities such as Snoop Dogg and Wiz Khalifa focus more on highly potent marijuana products. As such, the CBD market is much more attractive in the U.S. because of the passage of the Farm Bill in late 2018. The bill legalized hemp-derived CBD products as long as they contained 0.3% THC or less. Consequently, CBD products began to rapidly emerge throughout retailers across the country. However, industry experts believe that the recreational cannabis market will eventually dwarf the medical sector due to increasing legalization efforts. In particular, U.S. states such as California, Colorado, Nevada, and Washington are expected to contribute billions of dollars collectively to the global market. Moreover, Canada is also rapidly growing and is also projected to become a global revenue driver for the cannabis industry. And according to data compiled by MarketsandMarkets, the global cannabis market was valued at USD 10.3 Billion in 2018. By 2023, the market is expected to reach USD 39.4 Billion while exhibiting a CAGR of 30.7% during the forecast period. Pasha Brands Ltd. (OTC: CRFTF) (CSE: CRFT), Tilray, Inc. (NASDAQ: TLRY), Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON), Neptune Wellness Solutions Inc. (NASDAQ: NEPT) (TSX: NEPT), Charlotte's Web Holdings, Inc. (OTC: CWBHF) (TSX: CWEB)
Regulators Take Further Steps to Expand the Medical CBD Industry
- PR Newswire - Wed Nov 13, 8:00AM CST
PR Newswire - CMTX
Wed Nov 13, 8:00AM CST
The medical cannabis industry continued to progress after the National Health Services in England and Wales recently decided to approve cannabis-based medicines. Specifically, three treatments using medicinal cannabis were approved by the National Institute for Health and Care Excellence (NICE). As such, NICE noted that these cannabis-based medicines will be restricted to the treatment of only one of two rare forms of childhood epilepsy, multiple sclerosis, and chemotherapy-induced nausea. The institute also noted that all marijuana-based medications must be prescribed by specialist doctors. And an institute spokesman said that the recommendations could immediately be applied for England and Wales, with Northern Ireland expected to consider their use on a case-by-case basis, according to the New York Times. However, the rules do not apply in Scotland, which has its own healthcare guidelines. Generally, the approval by the constituent countries of the U.K. marks another major milestone within the cannabis industry. And England and Wales now join a handful of other international regions that have decided to move towards legalizing medical cannabis. For instance, major countries such as Australia, Canada, Colombia, France, Germany, Italy, Spain, and parts of the U.S. have all moved to adopt some sort of medical cannabis legislation. However, to note, most countries tend to have varying regulations on which specific ailments cannabis is eligible to treat. Nevertheless, as clinical trials continue to advance, industry experts believe that cannabis will become an important alternative treatment for numerous ailments. And according to data compiled by Fortune Business Insights, the global cannabis market was valued at USD 10.6 Billion in 2018. By 2026, the market is expected to reach USD 97.35 Billion while exhibiting a CAGR of 32.92% during the forecast period from 2019 to 2026. Pasha Brands Ltd. (OTC: CRFTF) (CSE: CRFT), Canopy Growth Corporation (NYSE: CGC) (TSX: WEED), Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON), Aphria Inc. (NYSE: APHA) (TSX: APHA), Aurora Cannabis Inc. (NYSE: ACB) (TSX: ACB)
Cronos Group Inc. Announces Third Quarter 2019 Results
- GlobeNewswire - Tue Nov 12, 6:00AM CST
GlobeNewswire - CMTX
Tue Nov 12, 6:00AM CST
Closed Redwood U.S. Hemp-Based Products Platform and Cronos Fermentation Facility Acquisitions
Cannabinoid Based Pharmaceuticals Could be Most Promising Segment of Cannabis Markets
- PR Newswire - Wed Nov 6, 7:45AM CST
PR Newswire - CMTX
Wed Nov 6, 7:45AM CST
Because almost every new projection for the global cannabis markets shows revenues continuing to rise together with an increasing growth rate, the recreational cannabis market has captured most of the media's attention, but there are other uses of the plant that are just as lucrative for companies. Medical cannabis is the other half of the industry that, although just as profitable, doesn't get as much coverage as the recreational side. Over the years, we've seen this sector grow from doctors prescribing marijuana to patients for pain symptoms all the way to sophisticated biotech and pharmaceutical companies developing new drugs to treat conditions like childhood epilepsy. A recent article by the Investing News Network concerning medical cannabis said: "One of the most promising cannabis markets of the future can be found in the healthcare industry as pharmaceutical companies jump on the opportunity to develop CBD-based drugs... The medical cannabis industry has had some remarkable achievements over the past several months, with new products, innovations and regulatory rulings opening up the market for cannabinoid-based pharmaceuticals. Biotech companies are recognizing this opportunity as they look to capture the growing cannabis pharmaceuticals market." Active cannabis companies in the industry making moves include: Aurora Cannabis Inc. (NYSE: ACB) (TSX: ACB), MCTC Holdings, Inc. (OTCPK: MCTC), The Supreme Cannabis Company, Inc. (TSX: FIRE) (OTCQX: SPRWF), Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON), Terra Tech Corp. (OTCQX: TRTC).
Meticulous Processes Allow Craft Cultivators to Grow Superior Cannabis
- PR Newswire - Thu Oct 31, 8:00AM CDT
PR Newswire - CMTX
Thu Oct 31, 8:00AM CDT
Following the recent legalization of cannabis in Canada and the continued efforts in the U.S., a plethora of recreational dispensaries began to emerge. Recreational dispensaries sell cannabis-based products such as flowers, oils, tinctures, topicals, and many others, which anyone can purchase as long as they are of legal age. Notably, dispensaries offer a variety of products suited to each individual's needs, as every individual consumer has a different tolerance level, meaning that the products may have varying effects. For instance, a 1:1 CBD to THC ratio is a balanced potency and is recommended for users who can handle the psychoactive properties of THC. On the other hand, less avid users are encouraged to purchase an 18:1 CBD to THC ratio product. An 18:1 ratio is high in CBD and is geared towards more novice users who don't intend to get "high," according to Care By Design. A CBD dominant product is typically used for relaxation purposes or to alleviate minor medical issues such as headaches or soreness. Generally, most recreational dispensaries tend to sell THC dominant products, however medical dispensaries are more likely to offer a mix of both. Additionally, CBD and THC levels within the plant can be altered by using special farming techniques. Meticulous growing processes can enable a plant to achieve the maximum cannabinoid density that a seed allows. For instance, cultivators growing high-THC flowers are looking to produce more trichomes on the plant. Trichomes can be found on various plants, however, on the cannabis plant, trichomes can determine the strain's potency and effectiveness. The outcome of the trichomes' growth can be manipulated by prolonging harvest time, changing light levels, and curing the bud. By achieving the maximum cannabinoid content, cultivators are tapping into a new market for consumers searching for a potent and premium-grade product. According to data compiled by Ameri Research, the global legal marijuana market was valued at USD 14.3 Billion in 2016. By 2024, legal marijuana global sales are projected to reach USD 63.5 Billion while exhibiting a CAGR of 21.1% from 2017 to 2024. Pasha Brands Ltd. (OTC: CRFTF) (CSE: CRFT), Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON), Aphria Inc. (NYSE: APHA) (TSX: APHA), Charlotte's Web Holdings, Inc. (OTC: CWBHF) (CSE: CWEB), Origin House (OTC: ORHOF) (CSE: OH)
Craft Cultivators Make Their Presence Felt in the Highly Competitive Cannabis Industry
- PR Newswire - Mon Oct 28, 8:00AM CDT
PR Newswire - CMTX
Mon Oct 28, 8:00AM CDT
While the cannabis industry was picking up steam, companies grappled to capture the attention of consumers. Specifically, in the U.S. and Canada, federal regulators provided limited amounts of operation licenses, meaning companies applying for licenses were aggressively competing against one another. However, early moving states like Colorado had originally opened 147 dispensaries in 2014 when the state first legalized adult-use. By 2018, Colorado had over 500 recreational dispensaries across the state. And while it is rewarding to obtain a license, it eventually makes it increasingly more difficult for companies to distinguish themselves against their competitors. In particular, many dispensaries aim to provide their consumers with high quality and potent products. However, most of these dispensaries usually do not grow their own cannabis or produce their own products. Typically, dispensaries purchase their products wholesale from licensed producers, which means that selecting the perfect producer can be time-consuming and tedious. Additionally, most wholesale licensed producers tend to lack quality in their products because of their large-scale grow houses. And as a result, many large producers can only provide mediocre cannabis at an affordable price. And while that may be agreeable for an infrequent consumer, it is not this way for all. Savvy consumers are more interested in unique products that are much more potent compared to standard strains. And it is the combination of the two different consumer spectrums that further accelerates the industry. According to data compiled by MarketsandMarkets, the global cannabis market was valued at USD 10.3 Billion in 2018. By 2023, the market is expected to reach USD 39.4 Billion while exhibiting a CAGR of 30.7% during the forecast period. Pasha Brands Ltd. (OTC: CRFTF) (CSE: CRFT), Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON), OrganiGram Holdings Inc. (NASDAQ: OGI) (TSX-V: OGI), Neptune Wellness Solutions Inc. (NASDAQ: NEPT) (TSX: NEPT), Charlotte's Web Holdings, Inc. (CWBHF) (CWEB).

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2020.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies